[ A21-120] Vericiguat (cardiac failure) - Benefit assessment according to §35a Social Code Book V
Last updated 03.03.2022
Project no.:
A21-120
Commission:
Commission awarded on 15.09.2021 by the Federal Joint Committee (G-BA).
Report type:
Dossier assessment
Status:
Commission completed
Department/Division:
Drug Assessment
Topic:
Heart and circulation
Adults with symptomatic chronic heart failure with reduced ejection fraction who are stabilized after a recent decompensation event requiring intravenous therapy
- Age < 75 years: hint of a non-quantifiable added benefit.
- Age ≥ 75 years: added benefit not proven.
After completion of the assessment by IQWiG the Federal Joint Committee (G-BA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the G-BA website.
| Project no. | Title | Status |
|---|---|---|
| A22-08 | Vericiguat (cardiac failure) - Addendum to Commission A21-120 | Commission completed |
Federal Joint Committee (G-BA)
2022-03-03 A G-BA decision was published.